Aeterna Zentaris to Present at Noble Capital Markets' 16th Annual Investor Conference
February 12 2020 - 8:05AM
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the
“Company”), specialty biopharmaceutical company commercializing and
developing therapeutics and diagnostic tests, today announced that
Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present
at NobleCon16 - Noble Capital Markets’ 16th Annual Investor
Conference on Monday, February 17th at 11:30 a.m. ET in Hollywood,
Florida.
As part of his presentation, Dr. Paulini will
provide a corporate overview and update on the Company’s lead
product, Macrilen™ (macimorelin), the only U.S. FDA and European
Commission approved oral test indicated for the diagnosis of adult
growth hormone deficiency (AGHD). Dr. Paulini’s slide presentation
will be made available on the Company’s website on Monday, February
17th.
In addition to the presentation, management will
be available to participate in investor meetings with registered
qualified investors attending the conference. To request a meeting,
please contact the NobleCon16 one-on-one desk.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty
biopharmaceutical company commercializing and developing
therapeutics and diagnostic tests. The Company’s lead product,
Macrilen™ (macimorelin) is the first and only U.S. FDA and European
Commission approved oral test indicated for the diagnosis of adult
growth hormone deficiency (AGHD). Macrilen™ is currently marketed
in the United States through a license agreement with Novo Nordisk
and Aeterna Zentaris receives double-digit royalties on sales.
Aeterna Zentaris owns all rights to macimorelin outside of the U.S.
and Canada.
Aeterna Zentaris is also leveraging the clinical
success and compelling safety profile of macimorelin to develop it
for the diagnosis of pediatric growth hormone deficiency (PGHD), an
area of significant unmet need.
The Company is actively pursuing business
development opportunities for the commercialization of macimorelin
in Europe and the rest of the world, in addition to other
non-strategic assets to monetize their value. For more information,
please visit the Company’s website at www.zentaris.com.
About Noble Capital Markets,
Inc.
Noble Capital Markets (“Noble”) is a research
driven boutique investment bank that has supported small &
microcap companies since 1984. As a FINRA and SEC licensed broker
dealer Noble provides institutional-quality equity research,
merchant and investment banking, wealth management and order
execution services. In 2005, Noble established NobleCon, an
investor conference that has grown substantially over the last
decade. In 2018 Noble launched www.channelchek.com – a new
investment community dedicated exclusively to small and micro-cap
companies and their industries. Channelchek is tailored to meet the
needs of self-directed investors and financial professionals.
Channelchek is the first service to offer institutional-quality
research to the public, for FREE at every level without a
subscription. More than 6,000 emerging growth companies are listed
on the site, with growing content including webcasts, podcasts, and
balanced news.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the Company's product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statement that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential, "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company's filings with the
Securities and Exchange Commission. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Investor Contact:
Jenene Thomas JTC Team T (US): +1 (833) 475-8247
E: aezs@jtcir.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Sep 2023 to Sep 2024